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chemoembolization (TACE)Abstract Purpose: To assess the treatment response of hepatocellular carcinoma (HCC) after
transarterial chemoembolization with diffusion weighted magnetic resonance (MR) imaging with
a 1.5 T system.
Materials and methods: Thirty patients with 30 HCC focal lesions were prospectively evaluated for
early treatment response after transarterial chemoembolization using dynamic contrast enhanced
MRI and diffusion weighted MRI before and after the procedure. Diameter of arterially enhancing
portions and apparent diffusion coefﬁcient (ADC) values of lesions were recorded. The signiﬁcance
of differences between ADC values of completely responding and partially responding lesions was
calculated.
Results: Tumor ADC value increased from 1.2 + 0.1 · 103 mm2/s to 1.49 + 0.3 · 103 mm2/s after
treatment (p< 0.001). There was a signiﬁcant positive correlation between the percent change in
the mean ADC and the percent change in the diameter of the enhancing tumor tissue after
chemoembolization. The best predictive cutoff value for differentiation between complete and
partial response was 24% change in the mean ADC.
Conclusion: Responding HCC lesions exhibited decreases in arterial enhancement and increases in
ADC values. Percent change in the mean ADC values was predictive of response to chemoem-
bolization.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common
malignancy in the world and the third most common cause
of cancer death (1).
Transarterial chemoembolization (TACE) of hepatocellular
carcinoma (HCC) is used as a bridge to liver transplantation.
872 Y.A. Ibrahim et al.It is also used for patients with unresectable HCC, and has
been shown to improve survival (2).
Early assessment of the effectiveness of TACE is critical in
planning future therapy (i.e., earlier treatment of residual
viable portions of the tumor, delaying re-treatment in cases
of good response to avoid unnecessary toxicity, or switching
to a different local–regional therapy approach) (3).
Assessment of tumor response after chemoembolization on
CT is generally based on tumor enhancement. However,
hyperattenuating iodized oil impairs the assessment of residual
tumor enhancement on contrast enhanced CT (4).
In contrast to CT, the high concentration of iodized oil
after chemoembolization does not affect MR signal intensity.
The disadvantage of contrast-enhanced MRI is the incapabil-
ity to distinguish viable cells from reactive granulation tissue.
After TACE an enhancing rim can appear on contrast-
enhanced MRI. This rim can correlate with either viable tumor
as well as to reactive tissue (4).
Diffusion-weighted imaging (DWI), a functional MRI tech-
nique, detects MR signal changes in tissues due to water pro-
ton motion that varies based upon the degree of cell membrane
integrity. The intact membranes of viable tumor cells restrict
water diffusion, whereas necrotic tumor cells with disrupted
cell membranes exhibit increased water diffusion. This mobil-
ity of water is quantiﬁed by a constant known as the apparent
diffusion coefﬁcient (ADC) (5).
It has been shown that hepatocellular carcinoma had a sig-
niﬁcant increase in ADC after transcatheter arterial chemoem-
bolization. DWI can determine treatment response several
weeks earlier than anatomical imaging (6).
The objective of this study is to evaluate the role of DWI
with ADC value measurement in follow-up of HCC after
transarterial chemoembolization.
2. Patients and methods
2.1. Patients
Thirty patients were included in this study which was per-
formed over a period of 1 year. They were all males, ranging
in age between 51 and 73 years with a mean age of 58.2 years.
All patients were diagnosed as HCC patients on a back-
ground of liver cirrhosis. Twenty-four patients were presented
with single hepatic focal lesion and six patients were presented
with multiple hepatic focal lesions, with a total number of 39
HCC focal lesions. Twenty-seven patients were positive for
HCV and three patients were positive for HBV infection.
Diagnosis of HCC was based on typical enhancement pat-
tern on triphasic CT scan with enhancement of the focal lesion
in the arterial phase and washout in the portovenous or
delayed phases.
All patients were prospectively studied. They were consid-
ered candidates for TACE. The decision of the treatment plan
was taken by a multidisciplinary team.
TACE was offered to BCLC-B HCC patients who ful-
ﬁlled the following inclusion criteria: patients with associated
Child’s A or B cirrhosis, normal main portal vein, less than
50% involvement of liver by HCC, and patients willing for
therapy and follow-up. Some patients of BCLC A, who were
unsuitable for ablative therapy or surgery, were also
included.The exclusion criteria included extra hepatic disease; coag-
ulopathy; biliary obstruction; comorbid illness such as coro-
nary artery disease, congestive heart failure, chronic renal
failure; and a previous history of encephalopathy/upper gas-
trointestinal bleed in the last 6 months.
All patients underwent one session of chemoembolization
for a total of 30 focal lesions. In patients with multiple HCC
focal lesions the largest one was selected.
All patients were subjected to the following:
 Laboratory investigations (aspartate and alanine amino-
transferases, alkaline phosphatase, gamma glutamyl-
transpeptidase, albumin, and total and direct bilirubin) in
addition to serum alpha fetoprotein levels before and one
month after chemoembolization.
 Abdominal MRI within 10 days before and about one
month after chemoembolization including pre- and post-
contrast dynamic MRI and diffusion-weighted imaging.
2.2. MRI imaging
A 1.5-T MR unit (Achieva; Philips Medical Systems, Best, the
Netherlands) was used, using a phased array coil to cover the
whole liver.
2.2.1. MR protocol
2.2.1.1. Pre-contrast imaging, with respiratory triggering
included.
– T1 weighted (T1W) in phase gradient echo sequence (GRE):
repetition time (TR) = 10 ms, echo time (TE) = 2.3 ms,
number of excitations (NEX) 2, ﬂip angle 15, matrix
150 · 236 with a ﬁeld of view as small as possible, slice
thickness 4 mm and slice gap 0.5 mm.
– T1 weighted (T1W) out of phase gradient echo sequence
(GRE): repetition time (TR) = 10 ms, echo time
(TE) = 4.6 ms, number of excitations (NEX) 2, ﬂip angle
15, matrix 150 · 236 with a ﬁeld of view as small as possi-
ble, slice thickness 4 mm and slice gap 0.5 mm.
– T1 weighted (T1W) gradient echo sequence (GRE) with fat
suppression (FS): repetition time (TR) = 100–200 ms, echo
time (TE) = 10 ms, number of excitations (NEX) 1, ﬂip
angle 15, matrix 150 · 236 with a ﬁeld of view as small
as possible, slice thickness 4 mm and slice gap 0.5 mm.
– T2 weighted (T2W) images (fast spin echo sequence) (FS):
TR= 2000 ms, TE = 90–120 ms, number of excitations
(NEX) 3, matrix 150 · 236 with a ﬁeld of view as small as
possible, slice thickness 4 mm and slice gap 0.5 mm.
2.2.1.2. Dynamic study. Dynamic study was performed after
bolus injection of 0.1 mmol/kg body weight of Gd-DTPA at
a rate of 2 ml/s, ﬂushed with 20 ml of sterile 0.9% saline solu-
tion from the antecubital vein. The injection of contrast media
and saline solution was performed using pump injector.
Breath-hold dynamic imaging using T1 weighted gradient
echo sequence, with fat suppression (thrive) was performed
in a triphasic manner [arterial phase (16–20 s), portovenous
phase (45–60 s) and delayed equilibrium phase (3–5 min)] after
administration of contrast media. Subtraction images were
also performed for arterial phase.
Fig. 1 (A and B) Histogram of a partially responding focal lesion
one day before (a) and one month after (b) chemoembolization
showing mild shift of the curve to the right. (C and D) Histogram
curve of completely responding focal lesion before (c) and after (d)
chemoembolization, showing blunting and shift of the curve to the
right side, consistent with resolution of diffusion restriction.
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single-shot echo-planar DW imaging was performed in the
transverse plane with tri-directional diffusion gradients by
using b values 0, 50, 200, 500 and 700 s/mm2. Parameters were
as follows: repetition time (TR) = 1852 ms, echo time
(TE) = 70 ms, number of excitations (NEX) = 3, matrix
150 · 236 with a ﬁeld of view as small as possible, slice thick-
ness 4 mm, slice gap 0.5 mm, scan time 5 min.
2.2.2. Imaging evaluation
 Conventional pre-contrast images were evaluated regarding
the signal intensity of the focal lesion on T1 and T2W
images.
 The dynamic post-contrast images were evaluated regarding
the enhancement pattern of the focal lesion, conﬁrmed on
subtraction images and the maximum transverse diameter
of the enhancing tumor tissue was measured in the arterial
phase images.
This was done before and after chemoembolization. The
percent reduction in the maximum transverse diameter of the
enhancing tumor tissue was calculated.
 The studied focal lesions were classiﬁed according to the
modiﬁed RECIST criteria for evaluation of HCC response
to treatment (7).
2.2.3. ADC calculation
The mean ADC of the focal lesion was calculated by position-
ing multiple regions of interest (ROI) over the tumor in consec-
utive image sections and then the mean ADC was calculated.
The ROIs may be placed directly onto the ADC map or copied
onto the map from those drawn on morphological or b-value
DW-MR images.
The individual voxel values in the ROI placed on the max-
imum transverse diameter of the focal lesion are used to gener-
ate ADC histograms. The histogram-based approach can be
also helpful to visualize tumor response to treatment by a
change in the shape or distribution of the histogram (Fig. 1).
Shift of the histogram to the right means higher ADC values
of the lesion and less cellularity which is in keeping with good
response to therapy.
2.3. Technique of chemoembolization
Chemoembolization was carried out at the interventional radi-
ology unit of Ain Shams University hospitals. A femoral arte-
rial approach was used with Seldinger technique. The hepatic
artery was catheterized with a 5F polyethylene catheter with
cobra head conﬁguration (C2 Cordis USA) in eighteen cases
and a reverse 5F catheter (Simmonds S2, Cordis USA) in
twelve cases. The catheter was advanced into the proximal
hepatic artery and an initial subtracted angiogram was
obtained after hand injection of 8 cc of nonionic contrast
(Ultravist 300; Schering, Berlin, Germany) to detect the
tumoral blush.
The catheter was further advanced so that the feeding
artery of the tumor was super selectively catheterized and in
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Boston Scientiﬁc, Natick, MA, USA).
TACE was done using a solution of emulsifying oily con-
trast agent (Lipiodol ultraﬂuid) and chemotherapeutic agents
(70–100 mg doxorubicin) mixed with water soluble contrast
and saline, using ﬂuoroscopic monitoring, the solution was
infused until initial slowing of antegrade blood ﬂow was noted.
TACE was then completed by injecting gel foam pledges
cut into small pieces mixed with water soluble contrast.
Embolization was done under ﬂuoroscopic guidance with
serial repeated control angiograms. Evidence of successful
embolization was deﬁned by complete stasis of the injected
contrast and embolizing material.Fig. 2 (A) Diffusion MRI done before chemoembolization of
right hepatic lobe HCC focal lesion, the focal lesion shows
diffusion restriction. (B) Diffusion MRI done one month after
chemoembolization, the focal lesion shows no diffusion restric-
tion. (C) Post-treatment dynamic contrast enhanced MRI arterial
phase image showing complete response of the focal lesion to
chemoembolization due to the absence of arterial enhancement.3. Results
Thirty patients with HCC were prospectively studied. The
mean duration between pretreatment MRI and chemoem-
bolization was 4 days (range, 0–9 days), and the mean duration
between treatment and post-treatment MRI was 32 days
(range, 25–51 days).
We classiﬁed the patients into two groups according to their
response on post-treatment dynamic MRI:
 Patients with complete response (who demonstrated com-
plete absence of arterial enhancement in the post-
treatment MRI) (Fig. 2).
 Patients with partial response (who showed residual tumor
arterial enhancement) (Figs. 3 and 4).
Unfortunately we did not have cases who met the
mRECIST criteria of nonresponse or stable disease.
Wilcoxon sign test was used to compare the mean diameter
of the enhancing tumor tissue, the mean tumor ADC value
before and after treatment. Results are summarized in
(Table 1).
Mann Whitney-test was used to compare different variables
among patients with complete response in comparison with
patients with partial response. Results are summarized in
(Table 2) and (Diagram 1).
According to (Spearman correlation test), there was a sig-
niﬁcant positive correlation between the percent change in
the mean ADC and the percent change in the diameter of
the enhancing tumor tissue after chemoembolization
(Diagram 2), with one unit change in the mean ADC associ-
ated with 0.048 unit change in the diameter of enhancing
tumor tissue.
Results of Receiver Operating Curve (ROC) analysis
revealed signiﬁcant correlation between the percent change in
the mean ADC and the percent change in the diameter of
the enhancing tumor tissue after treatment, the area under
the curve being 0.96 (Diagram 3).
The best predictive cutoff value for differentiation between
complete and partial response was 24% change in the mean
ADC, with 99% sensitivity, 84% speciﬁcity, 90% positive pre-
dictive value, 99% negative predictive value and 86% accu-
racy. The % change of the mean ADC is considered better
positive than negative predictor for response to treatment.
4. Discussion
Assessment of tumor viability after TACE is important for
evaluation of tumor response, subsequent treatment planning
and evaluation for liver transplantation. Although histopatho-
logic assessment of the treated tumor remains the most deﬁni-
tive method to determine viability, it is not feasible as a
method for follow-up (8).
Radiographic imaging is the predominant methodology for
assessment of tumor viability after chemoembolization (9).
In 2000, the European Association for the Study of the
Liver (EASL) proposed that the optimal method to evaluate
response to local treatment is to assess the reduction in viable
tumor volume, which is seen as a reduction in enhancing areas
on contrast-enhanced images (10).
Fig. 3 A 57 year old male patient presented with a single HCC focal lesion in the right lobe of the liver (segment V), measuring 4.6 cm in
its maximum transverse dimension. (A) Axial post-contrast GRE T1WI in the arterial phase showing heterogenous enhancement of the
focal lesion. There is washout of contrast in the delayed phase (B). On DWI, the lesion exhibits relative diffusion restriction compared to
the rest of hepatic parenchyma (C). The calculated mean ADC value is 1.163 · 103 mm2/sec. Transarterial hepatic angiography revealing
abnormal blush at the site of the focal lesion (D). Superselective catheterization (E) shows the focal lesion to take supply from two arteries,
the medial one being the principal feeder, with minor contribution from the lateral one. (F) Subtracted image showing lipiodol
concentration in the focal lesion. Follow-up dynamic MRI after one month revealed small residual viable tumor tissue at the right postero-
lateral margin of the focal lesion showing enhancement in the arterial phase (G) and washout in the delayed phase (H). Follow-up
diffusion MRI after one month (I), the focal lesion shows relative reduction in diffusion restriction, with a small residual diffusion
restriction at the right postero-lateral margin corresponding to the residual arterial enhancement.
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to chemoembolization is the modiﬁed RECIST criteria that
depend on arterial enhancement of the viable tumor tissue (7).
Residual viable tumor tissue is better depicted by
gadolinium-enhanced MR imaging that is barely inﬂuenced
by the presence of the iodized oil (11).
Several previous studies have shown the ability of DWI to
map water diffusivity within HCC tumors and quantify tumor
necrosis after chemoembolization:Kamel et al. (12,13) have conﬁrmed the feasibility of DWI
to measure tumor response, which shows an increase in the
ADC value at 4–6 wks after TACE. In their studies, regions
of increased ADC value corresponded to non-enhancing
regions of presumed coagulative necrosis on contrast-
enhanced MRI.
More recently Kamel et al. (6) have demonstrated ADC
changes as early as 1 wk post-TACE with no signiﬁcant
changes occurring at 1 day of follow-up.
Fig. 4 A51 year oldmalewith several right lobeHCC focal lesions. The largest onewas 6 cm in itsmaximumdimension andwas the target for
TACE.On pretreatmentDWI, the lesion showed diffusion restriction compared to the rest of hepatic parenchymawith estimatedADCvalue of
1.362 · 103 mm2/s (A).Other smaller hepatic focal lesionswerewell seen on theDWIbyvirtueof their diffusion restriction (B).Onemonthpost
chemoembolization the lesion showed 34% increase in mean ADC compared to pretreatment mean ADC (from 1.362 · 103 mm2/s to
1.702 · 103 mm2/s), however, there was a residual nodule with restricted diffusion on the DWI (C) noted in the posterior portion of the lesion
with corresponding low signal on theADCmap (D) and lowADCvaluemeasuring 0.384 · 103 mm2/s (D).This residual nodulewas evident on
the contrast enhanced MRI showing early arterial enhancement (E) with rapid washout in the portovenous phase (F).
Table 1 Comparison between pre- and post-treatment diam-
eter of enhancing tumor tissue and mean ADC value, SD
(Standard Deviation), HS (Highly Signiﬁcant).
Variables Pre (mean ± SD) Post (mean ± SD) P-value
Diameter 5.9 ± 1.7 1.5 ± 1.3 <0.001 (HS)
ADC 1.2 ± 0.1 1.49 ± 0.3 <0.001(HS)
Bold value indicates the signiﬁcant p values.
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scanner an increase in HCC ADC values as early as 2–3 days
after therapy.Chung et al. (5) had addressed the role of
intra-procedural DWI in predicting a future anatomical
response 1 month after TACE. Speciﬁcally, they showed that
patients whose ADC value increased or decreased fromTable 2 Comparison between patients with complete and partial res
(Highly Signiﬁcant), NS (Non-Signiﬁcant), pre (before chemoemboli
Variables Partial response (mean ± SD)
Diameter (pre) 6.9 ± 1.9
Diameter (post) 2.5 ± 1.8
% change in the diameter 65.2 ± 19
Mean ADC (pre) 1.2 ± 0.11
Mean ADC (post) 1.4 ± 0.2
% change in the ADC 11.6 ± 7
Bold value indicates the signiﬁcant p values.baseline by >15% immediately after TACE had a 100% rate
in predicting a positive EASL response after one month.
Several mechanisms can explain the increased ADC value
in necrotic tissue. It may be related to disruption or damage
of cellular membranes, which allows water to diffuse more
freely than in viable tumor (15,16).
Another explanation may be the decrease in tumor cellular-
ity in treated lesions. Some studies [17–20] have linked ADC to
tumor cellularity.
In the current study, the mean tumor ADC value increased
from 1.2 ± 0.1 · 103 mm2/sec to 1.49 ± 0.3 · 103 mm2/sec
after chemoembolization. ADC values obtained were lower
than the ADC values of focal lesions in the studies by
Kamel et al. (12,13) and Chen et al. (14), and higher than
the ADC values of the lesions in the studies by Sahin et al.
(21) and this may be a consequence of differences in parame-
ters of DWI, including the b values in our opinion.ponse regarding different statistical variables, S (Signiﬁcant), HS
zation), post (1 month after chemoembolization).
Complete response (mean ± SD) P value
4.9 ± 11 >0.05 NS
0 ± 0 <0.05 S
100 ± 0 <0.001 HS
1.2 ± 0.06 >0.05 NS
1.7 ± 0.2 <0.05 S
34.6 ± 10 <0.001 HS
Diagram 1 The percent change in the mean ADC of the tumor is
higher in patients with compete response than those with partial
response.
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ADC value, which is affected by tissue perfusion at low b-
values. This may confound measurement of tissue diffusivity
and cause higher ADCs by using lower b-values. The b values
used were 0 and 500 s/mm2 in the study by Chen et al. (14) and
0, 50, 400, and 800 s/mm2 in the study by Sahin et al. (21). The
b values used in the present study were 0, 50, 200, 500 and 700
s/mm2.
Also of note is the difference in the percent increase in the
mean ADC value after chemoembolization. In their study
(13,21), the increase in the mean ADC value of the focalDiagram 2 Scatter diagram, showing signiﬁcant positive corre-
lation between the % change in the mean ADC versus the % of
change in the diameter of the enhancing tumor tissue after
treatment, denoted by rising curve.lesions was 20% and 15.4% respectively, whereas, in the pre-
sent study, it was 11.6 ± 7% in patients with partial response,
and 34.6 ± 10% in patients with complete response with a sta-
tistically signiﬁcant difference between the two groups.
According to the current study, the best predictive cutoff
value for differentiation between complete and partial
response was 24% increase in the mean ADC value, with
99% sensitivity, 84% speciﬁcity, 90% positive predictive value,
99% negative predictive value and 86% accuracy. The %
increase in the mean ADC value is considered better positive
than negative predictor for complete response to treatment.
In addition, the current study showed a signiﬁcant positive
correlation between the percent increase in the mean ADC
value and the percent reduction in the diameter of the enhanc-
ing tumor tissue after chemoembolization. These results con-
solidate the belief that DWI is potentially useful for follow-
up after TACE by showing changes in the mean ADC value
of the focal lesion as an alternative to contrast-enhanced
MRI in the case of patients who cannot receive gadolinium
contrast material, such as patients with renal insufﬁciency at
risk of nephrogenic systemic ﬁbrosis.
Yuan et al. (22) proposed that high pretreatment mean
ADC values of HCC were predictive of poor response to
chemoembolization. In their study of 25 responding and 9
non-responding lesions, the threshold mean ADC value of
1.618 · 103 mm2/sec had 96.0% sensitivity and 77.8% speci-
ﬁcity for the identiﬁcation of non-responding lesions according
to ROC analysis. In the current study, there was no statisti-
cally signiﬁcant difference between patients with complete
and partial response as regards the pre-treatment mean ADC
value and this was in agreement with Sahin et al. (21).
However, further studies on this issue with larger numbers of
patients are needed to reach a ﬁrmer conclusion.
Homogenous thin rim enhancement around the tumor
on gadolinium-enhanced MR images represents
chemoembolization-induced vasculitis, inﬂammation, andDiagram 3 ROC curve showing signiﬁcant correlation between
the % change in the mean ADC of the tumor and the % change in
the diameter of the enhancing tumor tissue, with the area under
the curve being 0.96.
878 Y.A. Ibrahim et al.granulation tissue after local treatment (23). Contrast enhance-
ment in granulation tissue is believed to be caused by increased
capillary permeability and increased distribution of gadolin-
ium (4).
On the contrary, the presence of nodular ring enhancement
should cast doubt on local progression. Yet, it is still difﬁcult
to detect small residual areas located in the capsule. In those
situations, DWI may have a promising role in the differentia-
tion between necrosis and viable tumor, as ADC values
increase in the presence of necrosis (24).
As a part of selfcriticism, the present study itself has several
limitations. The most important one is that we could not per-
form histopathologic correlation, because patients were not
suitable for lesion resection or liver transplantation.
However, being a prospective study, we were able to standard-
ize the MR imaging protocol including the amount of contrast
media and the b values used in acquisition of the DWI.
In conclusion, DWI is a promising technique in the
response evaluation of HCC after TACE, depending on
the capability on microscopic tissue characterization and
water restriction. It facilitates distinction between viable
and necrotic tumor areas and helps the diagnosis of residual
or recurrent tumor. The percentage of change in the ADC
values before and after treatment could predict response to
therapy according to the present results. Future studies on
larger patient population with new technical developments
are needed to improve the image quality and sensitivity of
DWI.
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